MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers

PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Fricke, Stephanie L., Payne, Susan N., Favreau, Peter F., Kratz, Jeremy D., Pasch, Cheri A., Foley, Tyler M., Yueh, Alexander E., Van De Hey, Dana R., Depke, Mitchell G., Korkos, Demetra P., Sha, Gioia Chengcheng, DeStefanis, Rebecca A., Clipson, Linda, Burkard, Mark E., Lemmon, Kayla K., Parsons, Benjamin M., Kenny, Paraic A., Matkowskyj, Kristina A., Newton, Michael A., Skala, Melissa C., Deming, Dustin A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363831/
https://ncbi.nlm.nih.gov/pubmed/30425131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0510
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi